Blincyto | Leukemia | HK DengYueMedicine

Blincyto Application Scope

Blincyto (blinatumomab) is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in both adult and pediatric patients.

 

Blincyto Characteristics

• Ingredients: Blinatumomab (a bispecific T-cell engager [BiTE] antibody construct).

• Properties: A recombinant fusion protein that binds CD19 on B cells and CD3 on T cells, facilitating T-cell mediated cytotoxicity against malignant B cells.

• Specification: Supplied as a lyophilized powder for reconstitution.

• Packaging Specification: Provided in single-use vials (e.g., 35 µg/vial or 140 µg/vial); refer to the latest packaging details.

• Storage: Store at 2°C to 8°C and protect from light.

• Expiry Date: As specified on the product label (typically 36 months from the manufacturing date).

• Executive Standard: Manufactured under current Good Manufacturing Practices (cGMP) and relevant pharmacopeial standards.

• Approval Number: For example, US FDA NDA No. 208871 (subject to regional variations).

• Date of Revision: Refer to the most recent product labeling.

• Manufacturer: Amgen Inc.

Guidelines For The Use Of Blincyto

• Dosage and Administration: Administered as a continuous intravenous infusion over 28 days per treatment cycle with a stepwise dosing regimen (e.g., an initial lower dose followed by a higher maintenance dose). Specific dosing should be confirmed with the official prescribing information.

• Adverse Reactions: Common adverse events include cytokine release syndrome, neurological events, infections, and fever. Patients must be monitored closely.

• Contraindications: Contraindicated in patients with known hypersensitivity to blinatumomab or any of its components.

• Precautions: Monitor for cytokine release syndrome and neurotoxicity; dose adjustments may be necessary based on patient response.

Blincyto Interactions

Drug Interactions: Use caution when co-administering with immunosuppressants or other agents that affect T-cell function.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.
• Prescription drugs must be purchased from designated suppliers with a doctor’s prescription.